Abstract:Objective: Engineered immune cells (e.g., therapeutic T cells) provide a revolutionary approach to combat cancer. Certain activated immune cells can exquisitely sense and respond to the tumor microenvironment. Here, we propose a paradigm based on engineering macrophages to allow selective intercellular drug delivery and augmentation of antitumor activities by hijacking tumor microtube networks. Methods: Macrophages were engineered via anchoring lipopolysaccharides on the plasma membrane (LM). The tumor tropism of LM encapsulating doxorubicin (LM-Dox) was monitored by a real-time cell migration assay and small animal in vivo imaging. Monocyte chemoattractant protein-1 (CCL2) was measured by quantitative PCR and ELISA. Intercellular conduit formation was characterized by confocal laser scanning microscopy and scanning electron microscopy. LM-Dox activation of tumor-associated macrophages to release TNF-alpha was evaluated by western blot and immunofluorescence assays. The potential therapeutic effects of LM-Dox in a 3D tumor-immune model and a murine orthotopic lung cancer model were tested. Results: LM-Dox exhibited tumor tropism in response to CCL2 produced by A549 lung tumor cells and lung tumor tissues resulting in a remarkably higher amount of tumor accumulation than the case of Lipo-Dox (similar to 4-fold). Intriguingly, LM-Dox accumulated at tumor sites hijacked the established tumor microtube networks and even stimulated microtube formation with tumor cells but not with normal cells to enable selective and rapid transport of the drug to tumor cells. Simultaneously, LM-Dox induced secretion of TNF-alpha in tumor-associated macrophages, which increased the antitumor activity of Dox. Thus, LM-Dox increased the inhibitory effects on tumor growth and metastasis in a mouse orthotopic lung cancer model and minimized the side effects of Dox-induced tumor invasion. Conclusion: Lipopolysaccharide-anchored macrophages that can hijack tumor microtube networks for selective drug transport may serve as versatile bioactive carriers of anticancer drugs. In the clinical context, these engineered microphages represent a personalized medicine approach that can be translated into potential use of patient-derived monocytes/macrophages for drug delivery by means of cell-to-cell communication.

Monitoring the Interaction Between Solid Lipid Nanoparticles and Alveolar Macrophages via the Label-Free Technique

[Uptake of Monostearin Solid Lipid Nanoparticles by A549 Cells].

Utilizing Macrophages Missile for Sulfate-Based Nanomedicine Delivery in Lung Cancer Therapy

Understanding Macrophage Interaction with Antimony-Doped Tin Oxide Plasmonic Nanoparticles

Surface Engineering of Macrophages with Nanoparticles to Generate A Cell-Nanoparticle Hybrid Vehicle for Hypoxia-Targeted Drug Delivery

Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin

Nanomedicine engulfed by macrophages for targeted tumor therapy

Molecular scale study on the interactions of biocompatible nanoparticles with macrophage membrane and blood proteins

Lyotropic Liquid Crystalline Phase Nanostructure and Cholesterol Enhance Lipid Nanoparticle Mediated mRNA Transfection in Macrophages

Profiling alveolar macrophage responses to inhaled compounds using in vitro high content image analysis

An Expandable Mechanopharmaceutical Device (3): a Versatile Raman Spectral Cytometry Approach to Study the Drug Cargo Capacity of Individual Macrophages

Adjusting The Balance Between Effective Loading And Vector Migration Of Macrophage Vehicles To Deliver Nanoparticles

Softness Enhanced Macrophage-Mediated Therapy of Inhaled Apoptotic-Cell-inspired Nanosystems for Acute Lung Injury

Novel method to assess resident alveolar macrophage efferocytosis of apoptotic neutrophils by flow cytometry

Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases

A Preliminary Report Regarding the Morphological Changes of Nano-Enabled Pharmaceutical Formulation on Human Lung Carcinoma Monolayer and 3D Bronchial Microtissue

Lipopolysaccharide-anchored macrophages hijack tumor microtube networks for selective drug transport and augmentation of antitumor effects in orthotopic lung cancer.

Macrophages As an Active Tumour-Targeting Carrier of SN38-nanoparticles for Cancer Therapy

MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles

In situ label-free X-ray imaging for visualizing the localization of nanomedicines and subcellular architecture in intact single cells

Size and Time Dependent Internalization of Label-Free Nano-Graphene Oxide in Human Macrophages